"FDA Rejects MDMA for PTSD Amid Controversial Trials"
TL;DR Summary
FDA advisers voted overwhelmingly against approving MDMA for PTSD therapy due to significant flaws in clinical trials, including bias, missing data, and potential misconduct. Despite positive patient results, the trials' validity was questioned, and the FDA is still investigating possible data manipulation.
- Flawed, scandalous trials tank FDA expert support for MDMA therapy Ars Technica
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
- The psychedelic medicine revolution just took a big loss POLITICO
- FDA panel votes against MDMA for PTSD therapy BBC.com
- Why PTSD Is So Hard to Diagnose and Treat The New York Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
95%
921 → 42 words
Want the full story? Read the original article
Read on Ars Technica